Multiple sclerosis and depression

Multiple Sclerosis Journal

Volumn 17, Issue 11, 2011, Pages 1276-1281

  Feinstein, Anthony ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

brain imaging; depression; diagnosis; mortality; pathogenesis; treatment

Indexed keywords

DESIPRAMINE; GADOLINIUM; HYDROCORTISONE; PAROXETINE; PLACEBO; SERTRALINE;

ALCOHOL ABUSE; AMYGDALOID NUCLEUS; APPETITE DISORDER; ARCUATE FASCICULUS; BECK FAST SCREEN FOR DEPRESSION; BRAIN ATROPHY; CEREBROSPINAL FLUID; COGNITIVE THERAPY; CONSTIPATION; COPING BEHAVIOR; DEPRESSION; DIFFUSION TENSOR IMAGING; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; ELECTROCONVULSIVE THERAPY; EMOTION; FATIGUE; FRACTIONAL ANISOTROPY; FRONTAL LOBE; GRAY MATTER; HELPLESSNESS; HIPPOCAMPUS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HUMAN RELATION; HYDROCORTISONE BLOOD LEVEL; HYPOTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; MEMORY DISORDER; MINDFULNESS BASED INTERVENTION; MULTIPLE SCLEROSIS; NAUSEA; NORMAL APPEARING GRAY MATTER; NORMAL APPEARING WHITE MATTER; PHYSICAL DISABILITY; PREFRONTAL CORTEX; PSYCHOLOGIC TEST; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; RISK FACTOR; SOCIAL ISOLATION; STRESS; SUICIDAL IDEATION; SUPPORTIVE EXPRESSIVE THERAPY; TELETHERAPY; TEMPORAL LOBE; VENTROLATERAL PREFRONTAL CORTEX; WHITE MATTER; XEROSTOMIA;

EID: 80655144770     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511417835     Document Type: Review

References (49)

1. DAlisa S, Miscio G, Baudo S, Simone A, Tesio L, Mauro A. Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study. Disabil Rehabil. 2006 ; 28: 307-314
2. Arnett PA, Higginson CI, Voss WD, Wright B, Bender WI, Wurst JM, et al. Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning. Neuropsychology. 1999 ; 13: 434-446
3. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology. 2002 ; 59: 674-678
4. Feinstein A. Multiple sclerosis, depression and suicide. BMJ. 1997 ; 315: 691-692
5. Maybury CP, Brewin CR. Social relationships, knowledge and adjustment to multiple sclerosis. J Neurol Neurosurg Psychiatry. 1984 ; 47: 372-376
6. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon Beta-1b therapy for multiple sclerosis. Arch Neurol. 1997 ; 54: 531-533
7. Mohr DC, Hart SL, Fonareva I, Tasch ES. Treatment of depression for patients with multiple sclerosis in neurology clinics. Mult Scler. 2006 ; 12: 204-208
8. Sadovnik AD, Remick RA, Allen J, Swartz E, Yee IML, Eisen K, et al. Depression and multiple sclerosis. Neurology. 1996 ; 46: 628-632
9. Minden SL, Schiffer RB. Affective disorders in multiple sclerosis. Review and recommendations for clinical research. Arch Neurol. 1990 ; 47: 98-104
10. Kessler RC, McGonagle KA, Shanyang Z, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12 month prevalence of DSM-111-R psychiatric disorders in the United States. Results from the National Co-morbidity Survey. Arch Gen Psychiatry. 1994 ; 51: 8-19
11. Patten SB, Beck CA, Williams JVA, Barbui C, Metz LM. Major depression in multiple sclerosis. A population-based perspective. Neurology. 2003 ; 61: 1524-1527
12. Benedict RH, Fishman I, McClellan MM, Bakshi R, Weinstock-Guttman B. Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. Mult Scler. 2003 ; 9: 393-396
13. Honarmand K, Feinstein A. validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients. Mult Scler. 2009 ; 15: 1518-1524
14. Sadovnik AD, Eisen RN, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology. 1991 ; 41: 1193-1196
15. Stenager EN, Stenager E, Koch-Henrikson N, Brønnum-Hansen H, Hyllested K, Jensen K, et al. Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry. 1992 ; 55: 542-545
16. Patten SB, Lavorato DH, Metz LM. Clinical correlates of CES-D depressive symptom ratings in an MS population. Gen Hosp Psychiatry. 2005 ; 27: 439-445
17. Ron MA, Logsdail SJ. Psychiatric morbidity in multiple sclerosis: a clinical and MRI study. Psychol Med. 1989 ; 19: 887-895
18. Zabad RK, Patten SB, Metz LM. The association of depression with disease course in multiple sclerosis. Neurology. 2005 ; 64: 359-360
19. Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry. 2002 ; 159: 1862-1868
20. Benedict RHB, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa CW. Prediction of neuropsychological impairment in multiple sclerosis. Comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol. 2004 ; 61: 226-230
21. Ghaffar O, Chamelian L, Feinstein A. Neuroanatomy of pseudobulbar affect: a quantitative MRI study in multiple sclerosis. J Neurol. 2008 ; 253: 406-412
22. Pujol J, Bello J, Deus J, Marti-Vilalta JL, Capdevila A. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology. 1997 ; 49: 1105-1110
23. Bakshi R, Czarnecki D, Shaikh ZA, Priore RL, Janardhan V, Kaliszky Z. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. NeuroReport. 2000 ; 11: 1153-1158
24. Feinstein A, Roy P, Lobaugh N, Feinstein KJ, OConnor P. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology. 2004 ; 62: 586-590
25. Gold SM, Kern KC, OConnor MF, Montag MJ, Kim A, Yoo YS, et al. Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biol Psychiatry. :
26. Kiy G, Lehmann P, Hahn HK, Eling P, Kastruip A, Hildebrandt H. Decreased hippocampal volume, indirectly measured, is associated with depressive symptoms and consolidation deficits in multiple sclerosis. Mult Scler. :
27. Feinstein A, OConnor P, Akbar N, Moradzadeh L, Scott CJM, Lobaugh NJ. Diffusion tensor imaging abnormalities in depressed multiple sclerosis patients. Mult Scler. 2010 ; 16: 189-198
28. Sabatini U, Pozzilli C, Pantano P, Koudriavtseva T, Padovani A, Millefiorini E, et al. Involvement of the limbic system in multiple sclerosis patients with depressive disorders. Biol Psychiatry. 1996 ; 39: 970-975
29. Passamonti L, Cerasa A, Liguori M, Gioia MC, Valentino P, Nisticò R, et al. Neurobiological mechanisms underlying motional process in patients with relapsing-remitting multiple sclerosis. Brain. 2009 ; 132: 3380-3391
30. Feinstein A The clinical neuropsychiatry of multiple sclerosis. New York: Cambridge University Press ; 2007: 51-52.
31. Pakenham KI. Adjustment to multiple sclerosis: application of a stress coping model. Health Psychol. 1999 ; 18: 383-392
32. Arnett PA, Higginson CI, Voss WD, Randolph JJ, Grandey AA. Relationship between coping, cognitive dysfunction, and depression in multiple sclerosis. Clin Neuropsychol. 2002 ; 16: 341-355
33. Lynch SG, Kroencke DC, Denney DR. The relationship between disability and depression in multiple sclerosis: the role of uncertainty, coping and hope. Mult Scler. 2001 ; 7: 411-416
34. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z. Personal and family history of affective disorder. J Affect Disord. 1987 ; 12: 63-65
35. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multi-centre, randomized, double-blind placebo controlled trail. Neurology. 1993 ; 43: 655-661
36. Feinstein A, OConnor P, Feinstein KJ. Multiple sclerosis, interferon beta-1b and depression: a prospective investigation. J Neurol. 2002 ; 249: 815-820
37. Mohr DC, Likosky W, Dwyer P, van der Wende J, Boudewyn AC, Goodkin DE. Course of depression during the initiation of interferon Beta-1a for multiple sclerosis. Arch Neurol. 1999 ; 56: 1263-1265
38. Otte C, et al. Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. J Neurol Neurosurg Psychiatry. 2011 ; 82: 814-818
39. Fassbender K, Schmidt R, Mössner R, Kischka U, Kühnen J, Schwartz A, et al. Mood disorders and dysfunction of the hypothalamic-pituitary- adrenal axis in multiple sclerosis. Arch Neurol. 1998 ; 55: 66-72
40. Koch MW, Glazwnborg A, Uyttenboogaart M, Mostert J, De Keyser J. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Datab Syst Rev. 2011 ; 16: CD007295
41. Schiffer RB, Wineman NM. (1990) Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry. 1990 ; 147: 1493-1497
42. Ehde DM, Kraft GH, Chwastiak L, Sullivan MD, Gibbons LE, Bombardier CH, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008 ; 30: 40-48
43. Mohr DC, Boudewyn AC, Goodkin D, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group therapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001 ; 69: 942-949
44. Mohr DC, Hart SL, Julian L, Catledge JL, Honos-Webb L, Vella L. Telephone administered psychotherapy for depression. Arch Gen Psychiatry. 2005 ; 62: 1007-1014
45. Hind D, OCathain A, Cooper CL, Parry GD, Isaac CL, Rose A, et al. The acceptability of computerized cognitive behavior therapy for the treatment of depression in people with chronic physical disease: a qualitative study of people with multiple sclerosis. Psychol Health. 2010 ; 25: 699-712
46. Grossman P, Kappos L, Gensicke H, DSouza M, Mohr D, Penner IK, et al. MS quality of life, depression and fatigue improve after mindfulness training. Neurology. 2010 ; 75: 1141-1149
47. Rasmussen KG, Keegam BM. Electroconvulsive therapy in patients with multiple sclerosis. J ECT. 2007 ; 23: 179-180
48. Mattingley G, Baker K, Zorumski CF, Figiel GS. Multiple sclerosis and ECT: possible value of gadolinium enhanced magnetic resonance scans for identifying high risk patients. J Neuropsychiatr Clin Neurosci. 1992 ; 4: 145-151
49. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler. 2005 ; 11: 328-337